Corpus Intelligence IC Memo — MERCYONE ELKADER MEDICAL CENTER 2026-04-26 11:19 UTC
IC Memo — MERCYONE ELKADER MEDICAL CENTER
Investment Committee Memorandum | IA | 15 beds | Grade D | EBITDA uplift $911K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

MERCYONE ELKADER MEDICAL CENTER

CCN 161319 | CLAYTON, IA | 15 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

MERCYONE ELKADER MEDICAL CENTER is a 15-bed community hospital in CLAYTON, IA with $12.3M in net patient revenue and a 0.9% operating margin. The hospital serves a payer mix of 64.9% Medicare, 0.0% Medicaid, and 35.1% commercial.

Thesis: Turnaround. Our ML models identify $911K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 0.9% to 8.3% (+739bps).

Net Revenue HCRIS$12.3M
Current EBITDA COMPUTED$117K
Operating Margin COMPUTED0.9%
Occupancy HCRIS17.8%
Revenue / Bed COMPUTED$822K
Net-to-Gross HCRIS64.9%
Distress Probability MLnan%

2. Market Context & Competitive Position

124
IA Hospitals
-8.2%
State Median Margin
84
Comparable Hospitals

IA has 124 Medicare-certified hospitals with a median operating margin of -8.2%. The target's margin of 0.9% places it above the state median. Among 84 size-comparable peers (8-30 beds), the median margin is -8.1%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (8-30), prioritizing same-state peers. 84 hospitals in the comp set.

HospitalStateBedsRevenueMargin
MERCYONE ELKADER MEDICAL CENTE (Target)IA15$12.3M0.9%
PELLA REGIONAL HEALTH CENTERIA25$108.8M-16.6%
GREATER REGIONAL MEDICAL CENTEIA25$89.4M-4.4%
WINNESHIEK MEDICAL CENTERIA25$77.6M-0.1%
IOWA SPECIALTY HOSPITAL - CLARIA25$77.3M0.2%
MAHASKA HEALTH PARTNERSHIPIA25$75.6M-3.9%
WAVERLY HEALTH CENTERIA21$68.6M-8.6%
DELAWARE COUNTY MEMORIAL HOSPIIA25$66.5M-1.2%
UNITYPOINT HEALTH-MARSHALLTOWNIA27$65.9M-7.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $911K (739bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$259K+210bp18mo
Cost to Collect4.5%2.5%$247K+200bp12mo
Denial Rate Reduction12.0%6.5%$246K+199bp12mo
A/R Days Reduction5200.0%3800.0%$150K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+8bp6mo

5. EBITDA Bridge

Net Collection Rate
$259K
Cost to Collect
$247K
Denial Rate Reduction
$246K
A/R Days Reduction
$150K
Clean Claim Rate
$10K
Total EBITDA Uplift$911K
Current EBITDA$117K
+ RCM Uplift+$911K
Pro Forma EBITDA$1.0M
Current Margin0.9%
Pro Forma Margin8.3%
WC Released (1x)$473K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$180K$9.9M54.85x122.8%
Base (11x exit)10.0x11.0x$180K$10.9M60.66x127.3%
Bull Case9.0x11.0x$162K$14.0M86.30x143.9%
Bull (12x exit)9.0x12.0x$162K$15.3M94.44x148.3%
Bear Case11.0x10.0x$198K$5.3M26.59x92.7%
Bear (11x exit)11.0x11.0x$198K$5.9M29.57x96.9%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumHeavy Medicare dependenceMedicare comprises 64.9% of days; rate updates may lag inflation. Mitigant: CDI/CMI lever directly increases Medicare reimbursement
MediumLow occupancyAt 17.8%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 84 hospitals with 8-30 beds
  • Same-state prioritization (n=85)
  • Comp margins: P25=-13.3% / P50=-8.1% / P75=-2.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.